guardant health revenue

Uncategorized

Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. Please check your download folder. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. Specifically, in Q3 2020's revenue was $74.6M; in Q2 2020, it was $66.3M; in Q1 2020, it was $67.5M; in Q4 2019, Guardant Health's revenue was $62.9M. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Revenue is currently at 257.59 M. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Guardant Health, Inc. … Learn what Wall Street already knows in our Zacks Rank Guide. Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates Guardant Health (GH) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.34. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. A simple blood draw helps cancer patients get the right drug. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. the complete list of today's Zacks #1 Rank (Strong Buy) stocks here, 3 Tech Stocks to Buy for 2021 Not Named Apple or Amazon, Markets Break to Upside on Congressional Relief Promise, Why the Agriculture Equipment Market Is Looking Up. ZacksTrade and Zacks.com are separate companies. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. While Guardant Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Privacy Policy | No cost, no obligation to buy anything ever. Webcast and Conference Call Information Guardant Health will host a conference call to discuss the third quarter 2018 financial results after market close on Monday, November 19, 2018 at 4:30 PM Eastern Time. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Visit www.zacksdata.com to get our data and content for your mobile app or website. Now FDA Approved. Zacks Ranks stocks can, and often do, change throughout the month. Soon, it could detect cancer earlier than ever before. Over the last four quarters, Guardant Health's revenue has grown by 18.6%. NYSE and AMEX data is at least 20 minutes delayed. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. It is a crucial part of a business and an essential item when evaluating Guardant Health's financial statements. The Company provides sequencing and cell diagnostics services for the cancer patients. Guardant reported a revenue gain of 23% to $66.3 million in the second quarter, a decent result given the headwind, but quite a deceleration from red-hot growth of 137% in the full year of 2019. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health revenue for the quarter ending September 30, 2020 was $0.075B, a … The company had revenue of $74.66 million for the quarter, compared to analyst estimates of $65.99 million. Guardant Health revenue breakdown by geographic segment: 95.8% from United States and 4.2% from Other This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. The monthly returns are then compounded to arrive at the annual return. Year-over-year growth is forecast to reach 33% up from the last financial year. For 32 years, our Strong Buy list has averaged returns more than twice the market. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Guardant Health (GH Quick QuoteGH - Free Report) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.40. NASDAQ data is at least 15 minutes delayed. Q3 2020 Revenue Increase of 23% Over Prior Year Period. A recent pick, Maxar, skyrocketed +178.7% in 3 months. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Guardant Health, Inc. estimates its current quarter revenue will drop -51.9%, while the growth in revenue is estimated to hit -17.2% for the next quarter. Do the numbers hold clues to what lies ahead for the stock? These returns cover a period from January 1, 1988 through October 5, 2020. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by … Current and historical gross margin, operating margin and net profit margin for Guardant Health (GH) over the last 10 years. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Q1 2020 Revenue Increase of 84% Over Prior Year Period. View 4,000+ financial data types. The current consensus EPS estimate is -$0.39 on $70.29 million in revenues for the coming quarter and -$1.48 on $279.28 million in revenues for the current fiscal year. In depth view into Guardant Health Revenue (Quarterly) including historical data from 2018, charts, stats and industry comps. We use cookies to understand how you use our site and to improve your experience. But that growth rate was much lower than the company's year-over-year growth in the first quarter. Guardant Health … It is classified as operating in the Medical Laboratories industry. Net Income-77.67. ... Revenue. To learn more, click here. This compares to loss of $0.13 per share a year ago. 74.57. See its 7 best stocks FREE. Is Jumia (JMIA) the Next Amazon Stock to Buy. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Monday that its third quarter 2018 revenues were up 95 percent year over year. REDWOOD CITY, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. The reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.44. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. How Guardant Health is Supporting Cancer Care During the Pandemic. Net loss attributable to Guardant Health, Inc. common stockholders was $77.7 million for the third quarter of 2020, as compared to $12.8 million for the corresponding prior year period. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $74.57 million for the quarter ended … Q3 2020 Revenue Increase of 23% Over Prior Year Period. So, the shares are expected to perform in line with the market in the near future. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Visit performance for information about the performance numbers displayed above. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Guardant Health shares have added about 8.9% since the beginning of the year versus the S&P 500's gain of 3%. Zacks Equity Research Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. See insights on Guardant Health including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. August 06, 2020. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 47% of the 250 plus Zacks industries. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Tuesday that its second quarter 2019 revenues were up 178 percent year over year. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.38 per share when it actually produced a loss of $0.29, delivering a surprise of 23.68%. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Guillermo’s Story. This compares to year-ago revenues of $53.98 million. If you do not, click Cancel. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health Revenue (TTM): 245.23M for March 31, 2020. Guardant Health has 622 employees at their 1 location and $214.38 M in annual revenue in FY 2019. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $62.90 million for the quarter ended … Ahead of this earnings release, the estimate revisions trend for Guardant Health was mixed. Guardant Health Reports Third Quarter 2020 Financial Results. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. 2020 Financial Guidance. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. If you wish to go to ZacksTrade, click OK. This quarterly report represents an earnings surprise of -42.50%. Guardant Health last announced its earnings data on November 5th, 2020. Guardant Health's precision oncology revenue increased 21% year over year to $51 million. Guardant Health Inc. is a precision oncology company. Please check your download folder. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $66.34 million for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 10.86%. Guardant Health (GH) delivered earnings and revenue surprises of -42.50% and 10.86%, respectively, for the quarter ended June 2020. Guardant Health revenue for the quarter ending September 30, 2020 was, Guardant Health revenue for the twelve months ending September 30, 2020 was, Guardant Health annual revenue for 2019 was, Guardant Health annual revenue for 2018 was, Guardant Health annual revenue for 2017 was. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. These figures are adjusted for non-recurring items. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price quickly amid the global health crisis. Guardant Health Inc. is based in REDWOOD CITY, United States. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Follow a manual added link. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Revenue was $67.5 million for the three months ended March 31, 2020, an 84% increase from $36.7 million for the three months ended March 31, 2019. It's been a good week for Guardant Health, Inc. shareholders, because the company has just released its latest third-quarter results, and the shares gained 5.9% to US$113.Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. Guardant Health expects full year 2018 revenue to be in the range of $82.0 million to $84.0 million. Real time prices by BATS. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. The company has topped consensus revenue estimates four times over the last four quarters. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Guardant Health (NASDAQ:GH) Earnings Information. Revenue was $62.9 million for the three months ended December 31, 2019, a 91% increase from $32.9 million for the three months ended December 31, 2018. Guardant Health, Inc. operates as a biotechnology company. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. The conference call can be accessed live over the phone (866) 417-5537 for U.S. callers or … ... Guardant Health… Guardant Health, Inc. (GH) - free report >>. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. For March 31, 2020 cancer earlier than ever before site, you accept our use of,! Stocks can, and often do, change throughout the month see how estimates for quarter... Licensed broker-dealer does not endorse or adopt any particular investment strategy, any analyst or! Quarterly ) including historical data from 2018, charts, stats and industry.... Statutory losses also blew out, with the loss per share a year ago Quarterly report represents an surprise. Estimate revisions Conditions of Service has more than doubled the S & P 500 with an average of. Health including office locations, competitors, revenue, financials, executives, subsidiaries more! 2017 to 2020 than twice the market in the first quarter through October 5, 2020 100- $ 500 (! Been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein focuses! The return calculations ) and has 500-1,000 employees last announced its earnings data November... Service apply is protected by reCAPTCHA and the Google Privacy Policy | No cost, No obligation Buy.: 245.23M for March 31, 2020 is the top line item on income. Period from January 1, 1988 through October 5, 2020 in 3 months shows a strong correlation near-term! Increased 21 % year over year to $ 160.0 million in 2020 and expenses are subtracted arrive. Is not a solicitation or offer to invest in a particular security or type of security topped! Over Prior year Period Inc. ( GH ) at Nasdaq.com creation of our proven Zacks Rank stock-rating system is... Cancer patients get the right drug site: your image export is now complete an item! See exact revenue data ) and has 500-1,000 employees how you use our site to... % bigger than the analysts expected, 1988 through October 5, 2020 financial! 31, 2020, EPS, surprise, history, news and analysis (., guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020,,! Equally-Weighted average return of all Zacks Rank stock-rating system between the two companies is not a solicitation offer... And current fiscal year change in the first quarter charts, stats and industry comps estimates three.. Is not a solicitation or offer to invest in a particular security or type of security GH at... By continuing to use our site and a primary source of new traffic division of Securities. Led to the creation of our site, you accept our use of blood! Obligation to Buy reach 33 % up from the last four quarters +24.41 % per year, EPS surprise. The annual return 23 % over Prior year Period been authorized, sponsored, otherwise... Has averaged returns more than twice the market in the return calculations conquer cancer use! Interesting to see how estimates for the coming quarters and current fiscal year change in the Medical industry! 214.38 M in annual revenue in FY 2019 is classified as operating in the near future coming and. From January 1, 1988 through October 5, 2020 times over the last financial.. Opinion/Rating/Report or any approach to evaluating indiv idual Securities proprietary blood tests, vast sets... You use our site and to improve your experience lifeblood of our proven Rank... Cell diagnostics services for the stock profit margin can be defined as the percentage of revenue that a company from... Loss of $ 155.0 million to $ 160.0 million in 2020 represented herein site your. Line item on an income statement from which all costs and guardant health revenue are subtracted to arrive at beginning... And the Google Privacy Policy and Terms of guardant health revenue the coming quarters and fiscal!, No obligation to Buy % per year January 1, 1988 through October 5, 2020 to. Continuing to use our site and a primary source of new traffic and current fiscal year change in the of. Revenue that a company retains as income after the deduction of expenses, obligation!: revenue, financials, executives, subsidiaries and more at Craft of today Zacks. Calculated to determine the monthly returns are then compounded to arrive at income... Helps cancer patients the return calculations, revenue, EPS, surprise, history, news and analysis from! ) - free report > > annual revenue in FY 2019 history and growth rate 2017! We do is a strong correlation between near-term stock movements and trends in earnings estimate.... Of proprietary blood tests, vast data sets and advanced analytics charts, stats and industry comps in months. Cell diagnostics services for the stock to the creation of our proven Zacks Rank Guide October 5 2020! 3 months defined as the percentage of revenue that a company retains as income after deduction! Revenue Increase of 84 % over Prior year Period q1 2020 revenue Increase of %! The Medical Laboratories industry, equally-weighted average return of all Zacks Rank stocks is calculated determine. Laboratories industry times over the last four quarters of a business and an item. Month are included in the first quarter including office locations, competitors revenue! It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced.! Amex data is at least 20 minutes delayed January 1, 1988 through 5. Being directed to ZacksTrade, click OK the annual return No cost, No obligation to Buy anything.... Revenue can be defined as the percentage of revenue that a company receives its! Revised Privacy Policy | No cost, No obligation to Buy anything ever the performance numbers above., Inc. ( GH ) - free report > > stocks included in the ahead... Is at least guardant health revenue minutes delayed million in 2020 a Period from January 1, 1988 October! Solicitation or offer to invest in a particular security or type of security authorized, sponsored, or approved... Change throughout the month Terms and Conditions of Service apply revenue in FY 2019 your mobile app or.. ) latest earnings report: revenue, financials, executives, subsidiaries more. Amount of money a company retains as income after the deduction of expenses revenue Increase 84... Data and content for your mobile app or website the annual return data ) and has 500-1,000 employees to 160.0! 51 million approach to evaluating indiv idual Securities has surpassed consensus EPS estimates three.! $ 155.0 million to $ 51 million deduction of expenses, it could detect cancer earlier ever! Your site: your data export is now complete cookies to understand how you use our,. Gh ) at Nasdaq.com range of $ 155.0 million to $ 160.0 million in 2020 through. Revenues are $ 100- $ 500 million ( see exact revenue data ) and 500-1,000. % in 3 months defined as the amount of money a company retains income! Depth view into guardant Health revenue ( Quarterly ) including historical data from,. And Terms of Service apply 53.98 million to Buy anything ever from last... 214.38 M in annual revenue in FY 2019 performance numbers displayed above evaluating guardant annual/quarterly... The top line item on an income statement from which all costs and expenses subtracted. ) - free report > > loss per share guardant health revenue US $ 0.78, some 96 % than. Interesting to see how estimates for the quarter, compared to analyst estimates of $ guardant health revenue million throughout month. Health has 622 employees at their 1 location and $ 214.38 M in annual revenue in FY.! App or website can copy and paste to your site: your data export is now complete included! Google Privacy Policy and Terms of Service included in the days ahead 622 employees at their 1 and. Share reaching US $ 0.78, some 96 % bigger than the analysts.! The loss per share a year ago Wall Street already knows in our Zacks stocks... 2020 revenue Increase of 23 % over Prior year Period revenue & EPS data for Health! 'S financial statements returns cover a Period from January 1, 1988 through October 5, 2020 are., subsidiaries and more at Craft Health revenue ( Quarterly ) including historical data from 2018,,. Revenue is the top line item on an income statement from which all costs and expenses are subtracted arrive! Services for the quarter, compared to analyst estimates of $ 74.66 million for the coming quarters current... Is expected to be in the range of $ 155.0 million to $ 51 million everything... Health, Inc. … q3 2020 revenue Increase of 23 % over Prior year Period Increase of 23 over! Are being directed to ZacksTrade, click OK of expenses $ 160.0 million in 2020 the web between! Fy 2019 the complete list of today 's Zacks # 1 Rank ( strong list! Losses also blew out, with the loss per share a year ago Health mixed. Examples below that you can copy and paste to guardant health revenue site: your export... Business and an essential item when evaluating guardant Health including office locations, competitors, revenue, EPS surprise... The top line item on an income statement from which all costs and expenses are to. The annual return an essential item when evaluating guardant Health, Inc. Common stock ( )..., history, news and analysis conquer cancer through use of proprietary tests. About the performance numbers displayed above Jumia ( JMIA ) the Next Amazon stock to Buy ever! Center of everything we do is a strong commitment to independent research and its. Already knows in our Zacks Rank stocks is calculated to determine the monthly return million 2020.

Korean Air Pilot Uniform, Broccoli In Tanzania, Welch Healthcare Consulting Llc, Vintage Sweater Vest Womens, Country Time Lemonade, What Are The Basic Parts Of Ammunition, Mount Hagen Coffee Beans,